F.D.A. Approves a New Antipsychotic Drug
Published On Sep 26, 2024, 6:47 PM
The FDA has approved Cobenfy, the first new antipsychotic drug for schizophrenia in many years. Unlike existing treatments that block dopamine receptors, Cobenfy works by influencing acetylcholine levels, which may help address side effects like weight gain and lack of motivation that patients often experience. However, concerns remain regarding the long-term efficacy and potential side effects, as studies thus far have only lasted five weeks.
Stock Forecasts
BMY
Positive
Cobenfy could significantly improve treatment options for schizophrenia and potentially capture market share from existing drugs, particularly if it proves effective in the long term. Its novel approach may lead to better patient adherence to treatment due to fewer side effects.
Related News
Stock market today: Dow gains as Fed's favored inflation gauge cools
Sep 27, 2024, 2:45 PM
The market is looking to August's PCE print to calculate whether another jumbo cut is coming.
F.D.A. Approves a New Antipsychotic Drug
Sep 26, 2024, 6:47 PM
Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.